Literature DB >> 12685191

Ribonucleotide reductase immunoreactivity in adenocarcinoma cells and malignant or reactive mesothelial cells in serous effusions.

Hiroshi Okamura1, Toshiaki Kamei, Nobuo Sakuma, Nobuo Hanai, Tokuhiro Ishihara.   

Abstract

OBJECTIVE: Ribonucleotide reductase (RNR) is a cytoplasmic enzyme that is essential for DNA synthesis. Its activity is strongly associated with cell proliferation. We assessed the value of immunostaining for RNR in distinguishing between reactive mesothelia (RM), malignant mesotheliomas (MM) and adenocarcinomas (AC) in serous effusions. STUDY
DESIGN: Cytocentrifuged cell smears of serous effusions from 38 RM, 10 MM and 36 AC were immunostained with the monoclonal antibody KM1054 raised against the R2 subunit of RNR (RNR-R2) using the labeled streptavidin-biotin method. Quantitative RNR-R2 values were determined by counting the percentages of immunoreactive cells.
RESULTS: RNR-R2 immunostaining was confined to the cytoplasm. The median RNR-R2 value was 1.4% (range, 0-7.9%) for RM, 11.2% (4.1-15.3%) for MM and 12.1% (2.0-40.6%) for AC. Significant differences in RNR-R2 values were found for both AC versus RM (P < .001) and MM versus RM (P = .009). There was no difference between AC and MM (P = .26). An RNR-R2 value > or = 7% was found in 30 of 36 AC, 8 of 10 MM and 2 of 38 RM.
CONCLUSION: RNR-R2 immunostaining can be useful as an adjunct for differentiating AC or MM from RM in serous effusions.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12685191     DOI: 10.1159/000326506

Source DB:  PubMed          Journal:  Acta Cytol        ISSN: 0001-5547            Impact factor:   2.319


  3 in total

1.  Phase I study of GTI-2040, a ribonucleotide reductase antisense, with high dose cytarabine in patients with relapsed/refractory acute myeloid leukemia.

Authors:  Rebecca B Klisovic; William Blum; Zhongfa Liu; Zhiliang Xie; Cheryl Kefauver; Lenguyen Huynh; James A Zwiebel; Steven M Devine; John C Byrd; Michael R Grever; Kenneth K Chan; Guido Marcucci
Journal:  Leuk Lymphoma       Date:  2013-11-01

2.  Phase I study of GTI-2040, an antisense to ribonucleotide reductase, in combination with high-dose cytarabine in patients with acute myeloid leukemia.

Authors:  Rebecca B Klisovic; William Blum; Xiaohui Wei; Shujun Liu; Zhongfa Liu; Zhiliang Xie; Tamara Vukosavljevic; Cheryl Kefauver; Lenguyen Huynh; Jiuxia Pang; James A Zwiebel; Steven Devine; John C Byrd; Michael R Grever; Kenneth Chan; Guido Marcucci
Journal:  Clin Cancer Res       Date:  2008-06-15       Impact factor: 12.531

3.  The efficacy of the ribonucleotide reductase inhibitor Didox in preclinical models of AML.

Authors:  Guerry J Cook; David L Caudell; Howard L Elford; Timothy S Pardee
Journal:  PLoS One       Date:  2014-11-17       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.